Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe
Cancers · 22.10.2024 · 16 (21) · 3558
DOI: 10.3390/cancers16213558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 22.10.2024. Verfasst von Michael Weichenthal und 22 weiteren Autor:innen. Beteiligte Einrichtung: Skin Cancer Center Kiel, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck & Co., Inc., Rahway, NJ, USA, Merck Sharp & Dohme LLC, Merck & Co., Inc., Rahway, NJ, USA.
Abstract (Originalsprache)
Background
Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab as an adjuvant treatment for stage III melanoma.
Methods
We used the European Melanoma Registry (EUMelaReg), a disease entity-based registry specific for melanoma, to examine treatment and outcomes for adult patients with stage III melanoma with lymph node involvement who had complete resection and received adjuvant treatment with pembrolizumab. The primary objectives were to describe the demographic and clinical characteristics of the included patients as well as time on adjuvant pembrolizumab treatment (TOT), real-world recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) from adjuvant pembrolizumab initiation. Secondary objectives were time to next treatment (TTNT) after adjuvant use of pembrolizumab, next-line therapy for stage III and unresectable stage IV melanoma and overall survival (OS) from initiation of pembrolizumab.
Results
Patients were stratified according to age, sex, BRAF status, number of positive lymph nodes and disease substage. Median TOT was 11.1 (9.2–11.5) months, median RFS was 29.6 [18.7–not reached (NR)] months and median DMFS was 32.4 (22.7–NR) months. TTNT was 29.9 (22.2–NR) months, while median OS was not reached.
Conclusions
The results of this study offer insights into the real-world use of pembrolizumab as an adjuvant therapy for melanoma in Europe.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Skin Cancer Center Kiel, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.
- University Hospital of Zurich, 8091 Zurich, Switzerland.
- National Oncology Hospital Sofia, g.k. Darvenitsa, 1756 Sofia, Bulgaria.
- Instytut im. Marii Skłodowskiej-Curie, 02-781 Warsaw, Poland.
- Complex Oncology Center Plovdiv, 4004 Plovdiv, Bulgaria.
- Military Medical Academy (CSEEMEG), 11000 Belgrade, Serbia.
ORCID-Profile: Michael Weichenthal, Iwona Lugowska, Lidija Kandolf, Pawel Teterycz, Phil Cheng, Marc Bender, Helen Gogas, Ivan Marquez Rodas, Piotr Rutkowski, Dirk Schadendorf, Reinhard Dummer
Förderung
- Merck & Co., Inc., Rahway, NJ, USA
- Merck Sharp & Dohme LLC
- Merck & Co., Inc., Rahway, NJ, USA
Zitieren
APA
Weichenthal, M., Mangana, J., Gavrilova, I., Lugowska, I., Shalamanova, G. K., Kandolf, L., Chiarion-Sileni, V., Mohr, P., Karanikolova, T. S., Teterycz, P., Espinosa, E., Schnecko, P., Cheng, P., Bender, M., Jiang, S., Burke, T., Ascierto, P. A., Gogas, H., Rodas, I. M., …, & For The EUMelaReg Consortium (2024). Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe. Cancers, 16(21), 3558. https://doi.org/10.3390/cancers16213558
Vancouver
Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova GK, Kandolf L, et al. Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe. Cancers. 2024;16(21):3558. doi:10.3390/cancers16213558
BibTeX
@article{Weichenthal2024,
author = {Weichenthal, Michael and Mangana, Joanna and Gavrilova, Iva and Lugowska, Iwona and Shalamanova, Gergana Krumova and Kandolf, Lidija and Chiarion-Sileni, Vanna and Mohr, Peter and Karanikolova, Teodora Sotirova and Teterycz, Pawel and Espinosa, Enrique and Schnecko, Philipp and Cheng, Phil and Bender, Marc and Jiang, Shan and Burke, Thomas and Ascierto, Paolo Antonio and Gogas, Helen and Rodas, Ivan Marquez and Rutkowski, Piotr and Schadendorf, Dirk and Dummer, Reinhard and For The EUMelaReg Consortium},
title = {Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe},
journal = {Cancers},
year = {2024},
volume = {16},
number = {21},
pages = {3558},
doi = {10.3390/cancers16213558}
}
EUVIMED